Nanjing Immunophage Biotech Co., Ltd
Clinical trials sponsored by Nanjing Immunophage Biotech Co., Ltd, explained in plain language.
-
New drug IPG1094 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new drug called IPG1094 in about 60 adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study has two parts: first, finding a safe dose, the…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental pill called IPG7236 in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug can shrink or control the cancer. About 196 adults will take the pill twice…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for lupus patients: experimental drug targets kidney damage
Disease control Recruiting nowThis study is testing a new oral medication called IPG11406 for people with lupus nephritis, a kidney complication of lupus. The main goal is to check if the drug is safe and tolerable, and to see early signs it might help reduce kidney damage. About 36 adults aged 18 to 70 with …
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated May 04, 2026 16:23 UTC